Clinical Trial Detail

NCT ID NCT03580928
Title Acalabrutinib, Venetoclax, and Obinutuzumab for Initial Therapy of CLL (AVO)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Dana-Farber Cancer Institute
Indications

chronic lymphocytic leukemia

CLL/SLL

Therapies

Acalabrutinib + Obinutuzumab + Venetoclax

Age Groups: senior adult

No variant requirements are available.